Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Lipoprotein (a), [Lp(a)] has many properties in common with low-density lipoprotein, (LDL) but contains a unique protein apolipoprotein(a), linked to apolipoprotein B-100 by a single disulfide bond. There is a substantial size heterogeneity of apo(a), and generally smaller apo(a) sizes tend to correspond to higher plasma Lp(a) levels, but this relation is far from linear, underscoring the importance to assess allele-specific apo(a) levels. The presence of apo(a), a highly charged, carbohydrate-rich, hydrophilic protein may obscure key features of the LDL moiety and offer opportunities for binding to vessel wall elements. Recently, interest in Lp(a) has increased because studies over the past decade have confirmed and more robustly demonstrated a risk factor role of Lp(a) for cardiovascular disease. In particular, levels of Lp(a) carried in particles with smaller size apo(a) isoforms are associated with coronary artery disease (CAD). Other studies suggest that proinflammatory conditions may modulate risk factor properties of Lp(a). Further, Lp(a) may act as a preferential acceptor for proinflammatory oxidized phospholipids transferred from tissues or from other lipoproteins. However, at present only a limited number of agents (e.g., nicotinic acid and estrogen) has proven efficacy in lowering Lp(a) levels. Although Lp(a) has not been definitely established as a cardiovascular risk factor and no guidelines presently recommend intervention, Lp(a)-lowering therapy might offer benefits in subgroups of patients with high Lp(a) levels. Clin Trans Sci 2010; Volume 3: 327-332.

Original languageEnglish (US)
Pages (from-to)327-332
Number of pages6
JournalClinical and Translational Science
Volume3
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

Lipoprotein(a)
Cardiovascular Diseases
LDL Lipoproteins
Apolipoprotein B-100
Apoprotein(a)
Niacin
Disulfides
Lipoproteins
Coronary Artery Disease
Phospholipids
Protein Isoforms
Estrogens
Proteins
Alleles
Carbohydrates
Guidelines
Tissue

Keywords

  • Allele-specific apo(a) levels
  • Apo(a) size
  • Ethnicity
  • Lipoprotein(a)
  • Risk factors

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease. / Erdembileg, Anuurad; Byambaa, Enkhmaa; Berglund, Lars.

In: Clinical and Translational Science, Vol. 3, No. 6, 12.2010, p. 327-332.

Research output: Contribution to journalArticle

@article{f14ce1acd48d4e1692de1cb215f0cfa2,
title = "Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease",
abstract = "Lipoprotein (a), [Lp(a)] has many properties in common with low-density lipoprotein, (LDL) but contains a unique protein apolipoprotein(a), linked to apolipoprotein B-100 by a single disulfide bond. There is a substantial size heterogeneity of apo(a), and generally smaller apo(a) sizes tend to correspond to higher plasma Lp(a) levels, but this relation is far from linear, underscoring the importance to assess allele-specific apo(a) levels. The presence of apo(a), a highly charged, carbohydrate-rich, hydrophilic protein may obscure key features of the LDL moiety and offer opportunities for binding to vessel wall elements. Recently, interest in Lp(a) has increased because studies over the past decade have confirmed and more robustly demonstrated a risk factor role of Lp(a) for cardiovascular disease. In particular, levels of Lp(a) carried in particles with smaller size apo(a) isoforms are associated with coronary artery disease (CAD). Other studies suggest that proinflammatory conditions may modulate risk factor properties of Lp(a). Further, Lp(a) may act as a preferential acceptor for proinflammatory oxidized phospholipids transferred from tissues or from other lipoproteins. However, at present only a limited number of agents (e.g., nicotinic acid and estrogen) has proven efficacy in lowering Lp(a) levels. Although Lp(a) has not been definitely established as a cardiovascular risk factor and no guidelines presently recommend intervention, Lp(a)-lowering therapy might offer benefits in subgroups of patients with high Lp(a) levels. Clin Trans Sci 2010; Volume 3: 327-332.",
keywords = "Allele-specific apo(a) levels, Apo(a) size, Ethnicity, Lipoprotein(a), Risk factors",
author = "Anuurad Erdembileg and Enkhmaa Byambaa and Lars Berglund",
year = "2010",
month = "12",
doi = "10.1111/j.1752-8062.2010.00238.x",
language = "English (US)",
volume = "3",
pages = "327--332",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease

AU - Erdembileg, Anuurad

AU - Byambaa, Enkhmaa

AU - Berglund, Lars

PY - 2010/12

Y1 - 2010/12

N2 - Lipoprotein (a), [Lp(a)] has many properties in common with low-density lipoprotein, (LDL) but contains a unique protein apolipoprotein(a), linked to apolipoprotein B-100 by a single disulfide bond. There is a substantial size heterogeneity of apo(a), and generally smaller apo(a) sizes tend to correspond to higher plasma Lp(a) levels, but this relation is far from linear, underscoring the importance to assess allele-specific apo(a) levels. The presence of apo(a), a highly charged, carbohydrate-rich, hydrophilic protein may obscure key features of the LDL moiety and offer opportunities for binding to vessel wall elements. Recently, interest in Lp(a) has increased because studies over the past decade have confirmed and more robustly demonstrated a risk factor role of Lp(a) for cardiovascular disease. In particular, levels of Lp(a) carried in particles with smaller size apo(a) isoforms are associated with coronary artery disease (CAD). Other studies suggest that proinflammatory conditions may modulate risk factor properties of Lp(a). Further, Lp(a) may act as a preferential acceptor for proinflammatory oxidized phospholipids transferred from tissues or from other lipoproteins. However, at present only a limited number of agents (e.g., nicotinic acid and estrogen) has proven efficacy in lowering Lp(a) levels. Although Lp(a) has not been definitely established as a cardiovascular risk factor and no guidelines presently recommend intervention, Lp(a)-lowering therapy might offer benefits in subgroups of patients with high Lp(a) levels. Clin Trans Sci 2010; Volume 3: 327-332.

AB - Lipoprotein (a), [Lp(a)] has many properties in common with low-density lipoprotein, (LDL) but contains a unique protein apolipoprotein(a), linked to apolipoprotein B-100 by a single disulfide bond. There is a substantial size heterogeneity of apo(a), and generally smaller apo(a) sizes tend to correspond to higher plasma Lp(a) levels, but this relation is far from linear, underscoring the importance to assess allele-specific apo(a) levels. The presence of apo(a), a highly charged, carbohydrate-rich, hydrophilic protein may obscure key features of the LDL moiety and offer opportunities for binding to vessel wall elements. Recently, interest in Lp(a) has increased because studies over the past decade have confirmed and more robustly demonstrated a risk factor role of Lp(a) for cardiovascular disease. In particular, levels of Lp(a) carried in particles with smaller size apo(a) isoforms are associated with coronary artery disease (CAD). Other studies suggest that proinflammatory conditions may modulate risk factor properties of Lp(a). Further, Lp(a) may act as a preferential acceptor for proinflammatory oxidized phospholipids transferred from tissues or from other lipoproteins. However, at present only a limited number of agents (e.g., nicotinic acid and estrogen) has proven efficacy in lowering Lp(a) levels. Although Lp(a) has not been definitely established as a cardiovascular risk factor and no guidelines presently recommend intervention, Lp(a)-lowering therapy might offer benefits in subgroups of patients with high Lp(a) levels. Clin Trans Sci 2010; Volume 3: 327-332.

KW - Allele-specific apo(a) levels

KW - Apo(a) size

KW - Ethnicity

KW - Lipoprotein(a)

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=78650247664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650247664&partnerID=8YFLogxK

U2 - 10.1111/j.1752-8062.2010.00238.x

DO - 10.1111/j.1752-8062.2010.00238.x

M3 - Article

C2 - 21167011

AN - SCOPUS:78650247664

VL - 3

SP - 327

EP - 332

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 6

ER -